Latest News
Abbisko Therapeutics' FGFR4 inhibitor irpagratinib granted orphan designation in Europe for HCC
1 April 2026 - Chinese biopharmaceutical company Abbisko Therapeutics Co Ltd (HKEX:02256) announced on Tuesday that its independently developed, highly selective, oral small-molecule FGFR4 inhibitor irpagratinib (ABSK-011) has been granted Orphan Dru...
NJ Bio and Aji Bio-Pharma partner to strengthen support for ADC development
1 April 2026 - NJ Bio Inc, a US-based provider of integrated drug discovery and development services, and Ajinomoto Bio-Pharma Services (Aji Bio-Pharma), a Japan-based provider of biopharmaceutical manufacturing services and platform technologies, sa...
US FDA approves i-Lumen Scientific's i-SIGHT2 clinical study for dry AMD
1 April 2026 - i-Lumen Scientific Inc, a developer of non-invasive, bioelectric stimulation therapy innovations in ophthalmology for the treatment of intermediate to advanced dry age-related macular degeneration (AMD), announced on Tuesday that it ha...
Alltrna granted approval for first-in-human clinical trial of AP003
1 April 2026 - Transfer RNA (tRNA) developer Alltrna announced on Tuesday that it has received approval to initiate a Phase 1 clinical trial of AP003 in healthy volunteers in Australia.The study has been approved under Australia's Therapeutic Go...
Lilly to acquire Centessa Pharmaceuticals for up to USD47 per share
...